A recently published retrospective analysis of 185 patients who had advanced melanoma and discontinued PD-1-antibody treatment without progression or treatment-limiting toxicity, showed that patients in CR at the time of treatment discontinuation were less likely to progress (14%) than patients in PR (32%) or with SD (50%) [16]. The gene discussed is PDCD1; the disease is melanoma.